Vivos Therapeutics' DNA Appliance Receives FDA Clearance for Pediatric Sleep Apnea
核心洞察
Vivos Therapeutics (搜索) received FDA 510(k) clearance for its DNA oral appliance to treat moderate to severe obstructive sleep apnea (搜索) (OSA (搜索)) and snoring (搜索) in children aged 6-17.
Clinical trials showed a 50% reduction in sleep-related breathing disorder symptoms and a 58% decrease in snoring (搜索) among pediatric patients using the Vivos DNA appliance (搜索).
The DNA appliance (搜索) offers a non-invasive alternative to CPAP (搜索) or surgical interventions, potentially capturing a significant share of the pediatric OSA (搜索) market.
Vivos Therapeutics (搜索), Inc. (NASDAQ: VVOS) has announced FDA 510(k) clearance for its flagship DNA oral appliance, designed to treat moderate to severe obstructive sleep apnea (搜索) (OSA (搜索)) and snoring (搜索) in children aged 6 to 17. This clearance marks a significant milestone for Vivos, positioning the company to potentially disrupt the pediatric sleep apnea market with a non-invasive alternative to existing treatments.
Clinical Trial Results
The FDA approval was based on the results of a clinical trial involving 48 patients. The study demonstrated a significant reduction in sleep-related breathing disorder (SRBD) symptoms, decreasing from 0.28 to 0.14, representing a 50% improvement. Snoring (搜索) was also reduced by 58%. Furthermore, the improvement in moderate and severe Apnea-Hypopnea Index (AHI) measurements was 62.7%, with 96% of patients showing improvement or remaining stable. Notably, 92% of patients improved by greater than 50% or 1 classification in the moderate and severe categories, with 100% of the severe patients achieving this milestone. Airway volumes increased by 40% on average.
Device Details and Intended Use
The Vivos DNA appliance (搜索) is a non-invasive, removable oral appliance intended for children diagnosed with snoring (搜索) and/or OSA (搜索) requiring orthodontic treatment. The device is designed to be safe, comfortable, and affordable, offering a patient-friendly alternative to continuous positive airway pressure (CPAP (搜索)) therapy or surgical interventions.
Market Opportunity
Recent studies estimate that up to 10.1 million children in the U.S. (ages 6-17) suffer from pediatric OSA (搜索). Vivos believes that this FDA clearance presents a substantial opportunity to capture a significant share of this market. The company plans to leverage this approval by integrating pediatric care into its provider-based marketing and distribution model, aiming for rapid revenue scaling with minimal investment.
Vivos' Broader Portfolio
In November, Vivos also received FDA 510(k) clearance for treating severe OSA (搜索) in adults using its CARE (Complete Airway Repositioning and/or Expansion) oral appliances, which include the DNA, mRNA, and mmRNA devices. This earlier clearance positioned Vivos as the first company to offer an approved alternative to CPAP (搜索) or surgical neurostimulation implants for adults with severe OSA.